Action BDTX BLACK DIAMOND THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Black Diamond Therapeutics, Inc.

Actions

BDTX

US09203E1055

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 26/04/2024 		Varia. 5j. Varia. 1 janv.
5,89 USD +15,26% Graphique intraday de Black Diamond Therapeutics, Inc. +11,98% +109,61%
11/04 Black Diamond Therapeutics, Inc. annonce des changements au sein de son conseil d?administration et de ses comités CI
08/04 BLACK DIAMOND THERAPEUTICS, INC. : Wedbush persiste à l'achat ZM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Black Diamond Therapeutics, Inc. Announces Board and Committee Changes
Black Diamond Therapeutics Announces Changes to Board of Directors
Black Diamond Therapeutics Says BDTX-1535 Potentially Inhibits Non-Classical Mutations in Non-Small Cell Lung Cancer Patients
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Black Diamond: Q4 Earnings Snapshot
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
Black Diamond Therapeutics, Inc. Announces Resignation of Rajeev Shah from Board of Directors, Including as A Member of the Audit Committee of the Board
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
Black Diamond Therapeutics, Inc. Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BDTX
  4. Actualités Black Diamond Therapeutics, Inc.
  5. Autres langues